Kurser indlæses...

Prognose

Vi har ingen analytikerdata for denne virksomhed.

Nyheder Til nyhedsfeedet

Telo Genomics: blood test detects myeloma cells far more often than bone marrow standard

Telo Genomics reports that its blood-based TELO-MRD test detected circulating myeloma cells in 39 of 42 samples (92.9%) in a comparative study with the University of Athens, versus 23 of 42 samples (54.8%) with EuroFlow-NGF in bone marrow; the difference was statistically significant. The test combines quantification of circulating tumor cells with three-dimensional telomere analysis via the TeloView platform and measures minimal residual disease as well as genomic instability at the single-cell level. The study is based on a limited, paired cohort and requires confirmation in larger, independent studies. TELO-MRD is not yet commercially available; Telo Genomics aims for a market launch by the end of 2027 and estimates the addressable market for MRD tests in multiple myeloma at USD 300–400 million. » Mere på de.investing.com
Telo Genomics files provisional US patent application for blood-based myeloma MRD test

Telo Genomics has filed a provisional US patent application for a TeloView biomarker algorithm designed to determine minimal residual disease (MRD) in multiple myeloma from liquid biopsies and predict relapse risk. The filing also covers a workflow for isolating circulating cancer cells from peripheral blood; existing patent protection for TeloView runs until 2043. The company is running a study with the University of Athens to compare liquid-biopsy MRD results with EuroFlow, but notes that provisional applications do not guarantee eventual patents. Telo Genomics is under financial pressure (market capitalization ~USD 85 million, loss- and cash-flow-negative) and the stock is trading at USD 1.24. » Mere på de.investing.com
Telo Genomics raises private placement of convertible notes to $1.6m

Telo Genomics has increased the size of an unbrokered private placement of secured convertible notes from $1.2m to $1.6m. The notes carry a 15% annual interest rate, mature on December 15, 2026, and can be converted prior to maturity at $0.05 per share; early repayment by the company is excluded. For every $100,000 of convertible notes issued, 2,000,000 detachable warrants will be issued, exercisable within 12 months at $0.08. A first tranche brought in $840,000; additional tranches of up to $760,000 are to be placed by no later than March 6, 2026, with net proceeds to be used for working capital. The offering is subject to regulatory approvals and the stock trades at $1.25, near its 52-week low of $1.05. » Mere på de.investing.com

Virksomhedstal

I det seneste kvartal havde Telo Genomics en omsætning på 0 € og et nettoresultat på -407,16 t €

(EUR)	juni 2026	YoY
Omsætning	0	-
Bruttofortjeneste	-20,6 t	1.462,33 %
Nettoresultat	-407,16 t	25,80 %
EBITDA	-344,97 t	19,52 %

Fundamentale data

Nøgletal	Værdi
Markedsværdi	3,23 mio. €
Antal aktier	100,43 mio.
Højeste/laveste i 52 uger	0,0583 € - 0,0161 €
Udbytte	Nej
Beta	0,24
P/E (PE Ratio)	-2,17
PEG (PEG Ratio)	-0,02
K/I (PB Ratio)	-3,17
P/S (PS Ratio)	0,00

Virksomhedsprofil

Telo Genomics Corp., et biotekselskab, udvikler og kommercialiserer prædiktive teknologiske produkter til at tilpasse behandlingsplaner for patienter med bestemte sygdomme. Selskabet tilbyder en telomeranalyseplatform med diagnostiske og prognostiske anvendelser samt løsninger med flydende biopsier og relaterede teknologier inden for onkologi og neurologiske sygdomme. Selskabets vigtigste anvendelse er Telo-MM, en løsning, der giver lægefaglige fagpersoner handlingsorienteret information i behandlingen af multipelt myelom, en form for blodkræft. Dets løsninger omfatter også TeloView, en proprietær softwareplatform, der bruges til at kvantificere specifikke træk ved hver patients telomerer. Selskabet betjener patologer, klinikere, akademiske forskere og lægemiddeludviklere. Telo Genomics Corp. har en samarbejdsaftale med Mayo Clinic om at validere sine Telo-MM-tests for multipelt myelom. Selskabet var tidligere kendt som 3D Signatures Inc. og skiftede navn til Telo Genomics Corp. i april 2019. Telo Genomics Corp. blev stiftet i 2014 og har hovedsæde i Toronto, Canada.